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Overexpression of the transcriptional activator b-catenin, mostly owing to loss-of-function mutations of the adenomatous polyposis
coli (APC) tumour suppressor gene, is crucial for the initiation and progression of human colorectal carcinogenesis. Securin is a
regulator of chromosome separation and its overexpression has been shown to be involved in different tumour-promoting
processes, like transformation, hyperproliferation and angiogenesis, and correlates with tumour cell invasion. However, the molecular
mechanism leading to securin overexpression in human colorectal cancer is unknown. Here we show a correlated high expression of
b-catenin and securin (hPTTG1) in colorectal adenomas and carcinomas and further demonstrate that securin is a target of b-catenin
transcriptional activation. This implies that deregulation of the b-catenin/T-cell factor-signalling pathway leads to overexpression of
securin in human colorectal cancer, which subsequently may contribute to tumour progression.
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Loss-of-function mutations in the adenomatosis polyposis coli
(APC) tumour suppressor gene, resulting in deregulation of the
WNT-signalling pathway, has been associated with the progression
of the majority of colorectal carcinomas. The effect is an
accumulation of the coactivator protein b-catenin, which translo-
cates to the nucleus and functions as a composite transcription
factor together with the DNA-binding proteins of the T-cell factor
(TCF/LEF) family (Korinek et al, 1997). Several genes important
for development and tumorigenesis have been reported to be
regulated by b-catenin/TCF (see for review Brabletz et al, 2002).
The human securin (human pituitary tumour transforming gene,
hPTTG1) is an oncogene with little expression in normal adult
colon tissue (Zhang et al, 1999) in contrast to strong expression in
colorectal cancer (Heaney et al, 2000) and other human tumours
(Dominguez et al, 1998; Kakar, 1998; Shibata et al, 2002) and
several carcinoma cell lines (Kakar, 1998; Zhang et al, 1999).
Securin is essential for sister chromatid separation during mitosis
thereby regulating cell proliferation and chromosome stability
(Zou et al, 1999). Loss of securin function increases aneuploidy
(Jallepalli et al, 2001; Wang et al, 2001) and apoptosis, in part by
modulating p53 function (Yu et al, 2000; Bernal et al, 2002; Hamid
and Kakar, 2004). When overexpressed, securin increases c-myc
expression and results in elevated cell proliferation and non-
tumour cell transformation (Zhang et al, 1999; Hamid and Kakar,
2004). Furthermore, high expression of securin has been shown to
induce angiogenesis, possibly by activating basic fibroblast growth
factor and vascular endothelial growth factor expression (Zhang
et al, 1999; Ishikawa et al, 2001), and to correlate with tumour cell
invasion and metastasis (Zhang et al, 1999; Heaney et al, 2000;
Ramaswamy et al, 2003). Therefore, securin may contribute to
three important ‘hallmarks of cancer’ (Hanahan and Weinberg,
2000): transformation (‘self-sufficient growth’), angiogenesis and
invasion.
The molecular mechanism of securin regulation in colorectal
cancer is unknown. We investigated whether deregulation of the
b-catenin/TCF-signalling pathway leading to the accumulation
of b-catenin in colorectal carcinoma causes high expression of
securin in these tumours, which may contribute to tumour
progression and poor prognosis.
MATERIALS AND METHODS
Tissue specimen and immunohistochemistry
Formalin-fixed, paraffin-embedded colorectal adenocarcinomas
from patients who underwent surgery without additional treat-
ments were retrieved from the archive of the Department of
Pathology, University of Erlangen-Nu ¨rnberg. The study comprised
30 cases. Immunohistochemistry for b-catenin and Ki-67 was
performed as described previously (Hlubek et al, 2004). For
securin staining, a mouse anti-securin antibody (1:25; NovoCastra
NCL-SECURIN clone DCS-280.2, Newcastle, UK) and microwave
treatment for antigen retrieval was used.
RNA isolation and DNA microarray analysis
Detailed protocols and results will be published elsewhere (Hlubek
et al, in preparation). This study comprised well characterised
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smoderate-to-well differentiated colorectal adenocarcinomas and
mucosa from six patients. Total RNA was extracted from each
tissue sample using the RNeasy kit (Qiagen, Hilden, Germany)
including an DNA digest according to the manufacturer’s
instructions. Linear amplification of RNA was carried out
with the MessageAmp aRNA kit (Ambion, Huntingdon, UK).
Biotin-labelled cRNA was hybridised to the HG-U133A oligo-
nucleotide microarray (22283 probe sets, Affymetrix, Santa Clara,
CA, USA). All reactions were performed according to the
Affymetrix protocol.
For statistical analysis, the signals of each probe set were
summarised to a single expression value according to the standard
protocol of the chip manufacturer (MAS 5.0). The expression
values were transformed to log-2 scale and normalised by a non-
linear procedure based on a scatterplot smoother (Cleveland,
1977). All samples under investigation were normalised against
one expression signature that was used as reference. We made use
of Welch’s two-sample t-test in order to detect differential
expression between tumour tissue (T) and normal mucosa (N).
P-values were calculated and corrected in the multiple testing
context in order to obtain control over the false discovery rate
(FDR), that is, the fraction of false positives in a candidate list of
probe sets. Making use of the Benjamini–Hochberg procedure
(Benjamini and Hochberg, 1995) we identified a list of 3018
candidates from a total number of 22283 probe sets (set
FDR¼5%).
Special attention was paid to targets of the Wnt-signalling
pathway. A list of known b-catenin/TCF target genes was obtained
from the homepage of Joel Nusse (http://www. stanford.edu/
~rnusse/wntwindow.html) and expanded by recent reports found
in the literature (see for review Brabletz et al, 2005). Our list
contained a total number of 45 b-catenin/TCF target genes of
which 42 were represented by one or more probe sets on the
GeneChip array. We identified a cluster of 13 target genes
(including securin) that are (i) significantly regulated in the sense
that they are represented by at least one probe set contained in the
list of 3018 candidates and (ii) upregulated in tumour tissue
compared to normal mucosa.
Electromobility shift assay
The following sense and corresponding antisense oligonucleotides
were annealed and used as probes or for competition (500- and
100-fold molar excess): securin-TBE: 50-ATAAATCACTATCAAAG
GATAGAATTT-30; securin-mutTBE: 50-ATAAATCA CTGCCAAAG
GAT AGAATTT-30. Probes were end labelled and incubated with
0.5mg of bacterially expressed GST-TCF-4 DBD (DNA-binding
domain codon 265–496) or GST alone as described previously
(Hlubek et al, 2004).
DNA clones
The securin promoter–reporter plasmid (pGL-Sec. fl.) was
constructed by amplification of the primers U1 and D1 described
previously (Kakar, 1999) using the bacterial artificial chromosome
clone #RP11-35508 (BioCat, Heidelberg, Germany) as template.
The PCR product (nt  1336 to þ34; GenBank accession number
AF167560) was cloned into the pGL3basic (Promega, Mannheim,
Germany) reporter vector. For construction of the securin
promoter fragment (nt  1336 to 625; pGL-Sec frag.), the primers
U1 and PTTG1-625 (50-TTAAAAAATAAATCGAGAGGCTTT-30)
were used. Plasmids provided by other reseachers are as follows:
pGST-TCF4(DBD), pcDNA/hTCF4 and pcDNA/DN-TCF4 from
Bert Vogelstein (Johns Hopkins University, Baltimore, MD,
USA); pcDNAhb-catenin from Hans Clevers (University Medical
Center, Utrecht, The Netherlands).
Transfections and reporter assays
Human colon carcinoma cell lines SW480, DLD1 and HeLa
(human cervix carcinoma) cells were obtained from the American
Type Culture Collection (ATCC). Cells were cultivated under
standard conditions in Dulbecco’s modified Eagle’s medium
þ10% fetal bovine serum. Transfections and reporter assays
were carried out as described previously (Hlubek et al, 2004).
Experiments were conducted in triplicate and repeated at least
three times with similar results. Control plasmid (pcDNA3;
Invitrogen, Karlsruhe, Germany) was used to equalise for the total
amount of DNA and to keep the amount of background plasmid
constant.
RNA interference and quantitative real-time
reverse-transcription–PCR
Synthetic siRNA (Thermo Electron, Ulm, Germany) specific for
b-catenin (CAGUUGU GGUUAAGCUCUUdTdT) or GFP (AAG
CUACCUGUUCCAUGGCCAdTdT) as control and Oligofectamine
(Invitrogen, Karlsruhe, Germany) was used for transient transfec-
tion of the colorectal cancer cells according to the instructions of
the manufacturer. After 72h incubation time, cells were harvested,
total RNA isolated and real-time reverse transcription—PCR (RT–
PCR) was performed as described (Hlubek et al, 2004). The relative
quantities of securin-specific mRNA in b-catenin-siRNA- and
control-siRNA-transfected cells were determined for each sample
based on the Ct value from a standard curve generated for each
primer/probe set and normalised to the corresponding values of
the house-keeping gene b-actin.
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Figure 1 Similar expression pattern of securin (hPTTG1) and 12
established b-catenin/TCF target genes in tumour vs mucosa tissue
revealed by hierarchical clustering of microarray data (A). All 13 genes
are significantly upregulated in colorectal tumour tissue (T.1–T.6)
compared to corresponding normal mucosa (N.1–N.6). Gene expression
data are displayed as a heatplot with high expression encoded in red and
low gene expression shown in green relative to the mean expression
(black). Columns represent tissue samples with the corresponding
expression level of the individual genes located in rows. Overexpression
of securin in colorectal carcinoma (T) compared to mucosa (N) of seven
different cases analysed by real-time RT–PCR (B). Securin-specific mRNA
expression in seven tumour tissues relative to corresponding normal
mucosa was determined following normalisation to the matching
expression values of the housekeeping gene b-actin.
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sRESULTS
Overexpression of securin correlates with nuclear
b-catenin and Ki-67 expression in human colorectal
adenoma and carcinoma
DNA microarray analysis revealed significant overexpression of
securin (threefold, P-value o0.00001) in six human colorectal
carcinomas compared to the corresponding normal mucosa
(Figure 1A; detailed results will be published elsewhere (Hlubek
et al, in preparation). Similarly, securin overexpression was found
by real-time PCR analysis of seven different colorectal tumours
compared to the corresponding mucosa (Figure 1B). Thus, securin
shows a very similar differential expression pattern between tumour
and mucosa tissue like 12 other well-characterised b-catenin/TCF
target genes (fold changes between 3.3 and 1.8-fold, P-value o0.005;
Figure 1A). This observation gave rise to the hypothesis, that securin
is a target gene of b-catenin/TCF signalling, which is constitutively
active in these tumours. Therefore, we analysed the expression
pattern of b-catenin and securin protein in 30 colorectal adenocarci-
nomas by immunohistochemistry. We found a perfect correlation of
aberrant nuclear b-catenin expression and securin overexpression in
colorectal carcinoma and adenoma tissue, in contrast to very low and
restricted expression of securin at the colon crypt base in normal
mucosa. In line with securin function in mitosis, the proliferation
marker Ki-67 displayed the same expression pattern as securin and
nuclear b-catenin, indicating high proliferative activity of these
tumour cells (Figure 2 and Supplementary Figure 1). These results
support the hypothesis that accumulated b-catenin is an activator of
securin expression in human colorectal carcinoma.
b-Catenin binds to a TCF-binding site of the human
securin promoter
We searched for potential TCF-binding elements (TBE) in the securin
promoter/enhancer sequence (Kakar, 1999; Clem et al, 2003) as
b-catenin/TCF might directly regulate securin expression. Two sites
comprising the TBE motif (50-WWCAAAG-30) were identified (nt
 1064 to  1058, nt  796 to  790) and tested for interaction with
TCF-4 in electromobility shift assays (EMSA). One TBE (nt  1064 to
 1058; Figure 3A) was found to bind recombinant TCF-4 (Figure 3B),
which is consistent with the very recent report by Zhou et al (2005).
The TCF–DNA interaction was abrogated by specific competitor DNA
containing the wild-type TBE site (wt) whereas the mutant TBE motif
competitor (mt) had no effect (Figure 3B). Competitor DNA containing
the TBE of the c-myc promoter (myc) inhibited TCF binding to TBE to
the same extent. Mutant TBE-DNA showed no TCF binding and GST
protein alone did not bind to wild-type TBE (Figure 3B), indicating
s p e c i f i cb i n d i n go fT C F - 4t oT B Eo ft h esecurin promoter in vitro.
The human securin promoter is activated by b-catenin/TCF
The functional relevance of TCF-4 binding to the TBE motive was
investigated in luciferase reporter assays using a full-length securin
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Figure 2 Correlated overexpression of nuclear b-catenin, securin and Ki-67 in colorectal adenoma and carcinoma. Immunohistochemical detection of
b-catenin (first row), securin (second row) and Ki-67 (third row) using serial sections. Tissue sections show adenoma (a, a0,a 00), carcinoma (c, c0,c 00) and the
normal mucosa (arrows in a, a0,a 00 and b, b0,b 00) of the same case. Note that securin is already overexpressed in the adenoma tissue (arrowhead in a0) and
only weakly expressed in the underlying normal colon mucosa (arrow in a0). A substantial overexpression of securin, Ki-67 and nuclear b-catenin can be seen
in the carcinoma part (b, b0,b 00 and c, c0,c 00; the rectangle in b indicates the magnified area shown in c). Concordant with securin function in mitosis, the
proliferation marker Ki-67 displayed the same expression pattern as securin. Nuclear accumulation of b-catenin in many of these tumour cells may suggest a
function of this transcriptional activator protein for securin expression. Magnifications are indicated at the top of the figure.
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spromoter ( 1336 to þ34). In b-catenin-overexpressing colorectal
carcinoma cell lines SW480 and DLD1, the securin promoter (pGL
Sec fl.) exhibits strong transcriptional activity, 74 and 35-fold
over background (pGLbasic). Addition of dominant-negative
TCF-4 (dnTCF), which lacks the N-terminal b-catenin interaction
domain, reduced the securin promoter activity in a dose-dependent
manner by up to 51 and 44 % (Figure 4A and B). As it is known that
complete abrogation of b-catenin/TCF transcriptional activity by
dnTCF can induce a G1-phase arrest of the cell cycle (van de
Wetering et al, 2002) possibly influencing the cell cycle-dependent
expression of securin, we determined cell cycle progression by
fluorescence-activated cell sorting (FACS) analysis (Supplementary
Figure 2). Unsynchronised DLD1 and SW480 cells showed no
significant change in cell cycle phases after transient transfection
with dnTCF compared to cells transfected with control vector.
Furthermore, in HeLa cells, which do not have an activated
b-catenin/TCF-signalling pathway, the activity of the securin
promoter fragment ( 1336 to  625) was enhanced by over-
expression of TCF4 and b-catenin in a dose-dependent manner
(Figure 4C). Neither b-catenin nor TCF alone was able to activate
the securin promoter fragment. In addition, dnTCF abolished
promoter activation by b-catenin (Figure 4C).
Expression of endogenous human securin is regulated by
b-catenin
To test the regulatory function of b-catenin on the expression of the
endogenous securin gene in colorectal carcinoma cells, we utilised
TBE
probe
protein
competit.
Shift
Free
probe
–
++ + + ++ ++
–– –
wt
TCF GST TCF
wt
wt wt
wt wt wt wt
mt
mt
myc myc
wt wt
myc
TBE
Securin –1336
AP1 SP-1 SP-1 NF-Y AP2AP1 +1
ATCAAAG
–1064 –1058
–625
A
B
Figure 3 Identification of a TCF-binding element in the human securin
promoter. Structure of the human securin promoter (A). The TBE motif is
shown as a closed box and the corresponding nucleotide sequence as well
as the location relative to the transcription initiation site is indicated below
(not drawn to scale). Known transcription factor binding sites are shown
(Kakar, 1999; Clem et al, 2003). Electromobility shift assay shows specific
interaction of recombinant TCF-4 DNA-binding domain (TCF) with
oligonucleotides containing the wild-type TBE motif (TBE, wt) of the securin
promoter by complex formation (B, shift). Oligonucleotides were used as
labelled probes and as unlabelled competitors (competit.) in two different
amounts (wt, wild type; mt, mutant; myc, TBEs of the c-myc promoter as
positive control). Competition of wild-type securin TBE and c-myc TBE, but
not mutant TBE, indicates specific TCF-4 protein binding. The wild-type
DNA probe does not bind to GST protein alone nor does TCF bind to
mutant TBE (B).
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Figure 4 The b-catenin/TCF complex activates the human securin
promoter activity. Inhibition of securin promoter activity by dnTCF in
colorectal carcinoma cells with constitutively active b-catenin. The results of
the transient transfection reporter assays are shown as percentage of full-
length securin promoter activity (pGL Sec fl.; pGLbasic, vector control; A,
B). Securin promoter fragment (pGL Sec frag.) activity is enhanced by
b-catenin and TCF-4 in a dose-dependent manner. In contrast, transfection
of either b-catenin or TCF-4 alone does not augment securin promoter
activity (C). Results are represented as fold activation of promoter activity
by transfection of increasing amounts of b-catenin related to the vector
control transfected (pGLbasic). Cotransfection of dnTCF inhibits the
augmentation of securin promoter fragment activity induced by b-catenin.
The experiments were carried out in triplicate and repeated three times
with similar results.
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ssiRNA knockdown technology. The expression of endogenous
b-catenin was inhibited by transfection of HCT116, SW480 and
DLD1 colon cancer cells with b-catenin-specific siRNA. b-catenin
expression, measured by quantitative RT–PCR, was clearly reduced
compared to the control cells (transfected with green fluorescent
protein (GFP)-siRNA; Figure 5). Specific reduction of b-catenin
expression by b-catenin-specific siRNA transfection was confirmed
by Western blot in control experiments (Supplementary Figure 3;
see also Hlubek et al, 2004). Importantly, transfection of b-catenin-
specific siRNA decreased endogenous securin expression by 37, 43
and 56% compared to control cells, but not b-actin expression
(Figure 5, and Supplementary Figure 3). To exclude the possibility
that reduction of securin expression was caused by changes in cell
cycle progression, we performed control experiments using FACS
analysis. Transient transfection of HCT116 cells with b-catenin-
specific siRNA did not result in significant changes in the cell cycle
phase distribution (Supplementary Figure 4).
DISCUSSION
The results presented above demonstrate a correlated expression of
b-catenin, securin and Ki-67 in human colorectal adenomas and
carcinomas, indicating that securin is a potential b-catenin/TCF
target gene. In support of this hypothesis, we show that securin, like
12 well-known b-catenin/TCF target genes (e.g. c-myc, c-Met,
survivin and MMP7), is significantly overexpressed in colorectal
cancer compared to normal mucosa using DNA microarray analysis,
real-time PCR and immunohistochemistry. Moreover, we found a
functional TCF-binding element in the securin promoter sequence
identical to the TBE found to be functional in esophageal squamous
cell carcinoma, published during the preparation of this manuscript
(Zhou et al, 2005). In EMSA experiments, we show specific TCF–
DNA interaction. The functional relevance of this interaction is
shown by reporter-gene experiments in colorectal cancer cell lines
demonstrating that dnTCF inhibits securin promoter activity in a
dose-dependent manner. As securin expression is cell cycle
dependent, peaking in mitosis (Ramos-Morales et al,2 0 0 0 ) ,a n d
b-catenin can influence cell cycle progression by regulating c-myc
expression (van de Wetering et al, 2002), we performed FACS
anaylsis. However, we did not observe significant differences in cell
cycle progression beween dnTCF-transfected and control vector-
tranfected cells (Supplementary Figure 2). The transient transfection
of dnTCF or b-catenin siRNA (see below) reduces b-catenin
transcriptional activity, but does not completely abolish it, which
would be necessary for inducing a G1-phase arrest of the cell cycle
(van de Wetering et al, 2002, 2003).
Additionally, we show that securin promoter fragment contain-
ing the TBE is activated in HeLa cells by overexpression of TCF-4
and b-catenin, but not by either protein alone. However, we were
unable to activate the full-length promoter construct significantly
by overexpression of TCF-4 and b-catenin, because the promoter
region (659 nucleotides) proximal to the transcriptional start site
contains additional regulatory elements (Kakar, 1999; Clem et al,
2003) presumably obscuring this effect. We tested the function of
b-catenin/TCF in the regulation of the endogenous securin gene by
transfection of colorectal carcinoma cells with b-catenin-specific
siRNA. Owing to the transient transfection procedure used, no
complete abrogation of b-catenin expression was observed and cell
cycle progression was not changed. However, a potent inhibition of
b-catenin expression was induced, resulting in a significant
reduction of the endogenous securin gene expression. Even though
we do not exclude the possibility of an indirect effect of b-catenin
on securin expression by affecting cell cycle progression, our
results show the relevance of b-catenin for the direct regulation of
securin gene expression in colorectal tumour cells.
The oncogene securin is deregulated in many human tumours
and is able to contribute to several main aspects of tumorigenesis.
In several tumours, overexpression of securin is associated
with tumour metastasis and poor clinical outcome and has been
identified as a significant prognostic marker in esophageal
carcinoma (Zhang et al, 1999; Heaney et al, 2000; Shibata et al,
2002; Ramaswamy et al, 2003). The identification of securin as
a Wnt target gene activated early in the adenoma–carcinoma
sequence further supports a decisive role of aberrant over-
expression of b-catenin in all phases of colorectal carcinogenesis.
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